Amylyx Pharmaceuticals announced Thursday that it has begun the process of voluntarily withdrawing its ALS drug, Relyvrio, from the market after it failed to prove efficacy in a large clinical trial.Video above: A one-minute history of ALS, also known as Lou Gehrig's disease'Relyvrio will no longer be available for new patients as of today.
'We commend Amylyx for pulling Relyvrio off the market, while still ensuring that people living with ALS can access the drug if they believe it is helping them,' the nonprofit ALS Association said in a statement. 'ALS is a fatal and heterogenous disease with few treatment options, and creative solutions are needed.'ALS, also known as Lou Gehrig's disease, affects as many as 30,000 people in the United States.
เราได้สรุปข่าวนี้มาให้อ่านอย่างรวดเร็ว หากสนใจข่าว สามารถอ่านฉบับเต็มได้ที่นี่ อ่านเพิ่มเติม:
ประเทศไทย ข่าวล่าสุด, ประเทศไทย หัวข้อข่าว
Similar News:คุณยังสามารถอ่านข่าวที่คล้ายกันนี้ซึ่งเรารวบรวมจากแหล่งข่าวอื่น ๆ ได้
Why Amylyx is pulling ALS drug Relyvrio from US market after studyThe maker of a drug for Lou Gehrig’s disease that recently failed in a study says it will pull the medicine from the U.S. market. Amylyx Pharmaceuticals said Thursday it will halt marketing in the U.S. and Canada. In March, the drugmaker announced that its drug had failed to show any benefit for patients in a 600-person study.
แหล่ง: AP - 🏆 728. / 51 อ่านเพิ่มเติม »
Here’s Why ALS Drug Relyvrio Is Being Removed From Market—And What That Means For PatientsI'm a Texas native covering the latest trends in tech, science and healthcare through explainer pieces on the breaking news team. Previously, I was a Forbes HBCU Scholar writing under the innovation and health and science teams.
แหล่ง: ForbesTech - 🏆 318. / 59 อ่านเพิ่มเติม »
Controversial ALS Drug May Be Pulled from Market After Disappointing Trial ResultsFollowing disappointing trial results, the maker of a controversial ALS drug may pull the medication off the market. Amylyx Pharmaceuticals is considering voluntarily withdrawing the drug, Relyvrio/Albrioza, after it failed to help patients in a large follow-up study. The company has decided to pause promotion of the medication and will announce their plans for the drug in the next two months.
แหล่ง: MedicineNet - 🏆 575. / 51 อ่านเพิ่มเติม »